US2022074946A1PendingUtilityA1

Peptide array quality control

Assignee: UNIV ARIZONA STATEPriority: Mar 15, 2013Filed: Jul 19, 2021Published: Mar 10, 2022
Est. expiryMar 15, 2033(~6.6 yrs left)· nominal 20-yr term from priority
G01N 33/6845
75
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present application provides arrays for use in immunosignaturing and quality control of such arrays. Also disclosed are peptide arrays and uses thereof for diagnostics, therapeutics and research.

Claims

exact text as granted — not AI-modified
1 . (canceled) 
     
     
         2 . A method for determining quality and fidelity of an in situ synthesized immunosignature array, comprising:
 obtaining a first distribution of binding intensities of a first in situ synthesized immunosignature array by:
 binding with a sample from a subject; and 
 detecting binding intensities of the sample over a population of features thereby determining the first distribution of binding intensities over the population of features; 
   obtaining a second distribution of binding intensities of a second in situ synthesized immunosignature array; and   comparing the distributions of binding intensities of the first in situ synthesized immunosignature array with the second in situ synthesized immunosignature array, thereby establishing synthesis quality and fidelity of each in situ synthesized peptide array.   
     
     
         3 . The method of  claim 2 , wherein the sample is a blood sample, a serum sample, a plasma sample, a urine sample, a sputum sample, a mucosal sample, a peritoneal fluid sample, a tissue sample, an exudate or an effusion. 
     
     
         4 . The method of  claim 2 , wherein the sample is obtained from a human. 
     
     
         5 . The method of  claim 2 , wherein the first and second in situ synthesized immunosignature array is a random or partially random peptide array. 
     
     
         6 . The method of  claim 2 , wherein the first distribution of binding intensities is obtained from binding with a first sample, and wherein the second distribution of binding intensities is obtained from binding with a second sample, wherein the first sample and the second sample are from a same species. 
     
     
         7 . The method of  claim 6 , wherein the first sample and the second sample are not from the same subject. 
     
     
         8 . The method of  claim 7 , wherein the first sample and the second sample are acquired from a blood sample. 
     
     
         9 . The method of  claim 2 , wherein comparing the distributions of binding intensities of the first in situ synthesized immunosignature array and the second in situ synthesized immunosignature array comprises comparing the shape of the distributions of binding intensities. 
     
     
         10 . The method of  claim 2 , wherein detecting binding intensities of the biological sample over the population of features comprises fluorescence imaging techniques. 
     
     
         11 . The method of  claim 2 , wherein the population of features comprises different peptide features immobilized on the in situ synthesized immunosignature array. 
     
     
         12 . A method for determining the quality of a batch of biopolymer arrays, comprising:
 obtaining a binding pattern of at least two arrays of a batch;   obtaining a correlation value of the binding pattern between the at least two arrays; and   comparing the correlation value with a correlation range,   wherein a correlation value of less than a threshold level indicates a fidelity of the biopolymer array.   
     
     
         13 . The method of  claim 12 , wherein correlation values of the binding patterns are obtained between all possible pairs of arrays of the batch. 
     
     
         14 . The method of  claim 13 , wherein the correlation value comprises a correlation coefficient. 
     
     
         15 . The method of  claim 14 , wherein the correlation coefficient is obtained by Kolmogorov-Smirnov test. 
     
     
         16 . The method of  claim 12 , wherein the threshold level comprises a percentage of the correlation coefficient between assays. 
     
     
         17 . The method of  claim 16 , wherein the threshold level is at least under 3%, at least under 4%, at least under 5%, at least under 6%, at least under 7%, at least under 8%, at least under 9%, at least under 10%, at least under 15%, at least under 20%, at least under 25%, at least under 30%, at least under 35%, at least under 40%, at least under 45%, or at least under 50%. 
     
     
         18 . The method of  claim 12 , wherein the threshold level comprises a standard deviation derived from calculation of a plurality of correlation coefficients between an assay and a standard assay. 
     
     
         19 . The method of  claim 18 , wherein the threshold level is at least under two standard deviations, at least under two and one-half standard deviations, at least under three standard deviations, at least under three and one-half standard deviations, or at least under four standard deviations. 
     
     
         20 . The method of  claim 12 , wherein the biopolymer comprises a peptide or polynucleotide. 
     
     
         21 . The method of  claim 12 , wherein the biopolymer array comprises a random peptide array.

Join the waitlist — get patent alerts

Track US2022074946A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.